Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 43598-999

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 43598-999). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Label for Venlafaxine Hydrochloride Extended-Release Capsules, USP 37.5 mg by Dr. Reddy's Laboratories Inc. The label indicates the product contains 30 capsules and includes the NDC 43598-999-30. It provides a QR code and website link for the medication guide and states storage conditions and manufacturer information.*

FDA Label Image

Container2 (Container2)

Label for Venlafaxine Hydrochloride Extended-Release Capsules, USP 75 mg, by Dr. Reddys Laboratories Inc. The package contains 30 capsules. The label includes a note to dispense the enclosed Medication Guide, NDC 43598-001-30, storage instructions, and a QR code linking to the Medication Guide online.*

FDA Label Image

Container3 (Container3)

Label for venlafaxine hydrochloride extended-release capsules, USP 150 mg, from Dr. Reddys Laboratories Inc. The label indicates a package size of 30 capsules and includes pharmacist instructions to dispense the enclosed medication guide. Storage instructions and regulatory information are also visible, along with a barcode and a QR code linking to the medication guide.*

FDA Label Image

Figure1 (Figure1)

A forest plot chart displaying fold change and 90% confidence intervals for venlafaxine pharmacokinetics (Cmax and AUC) across special populations including hepatic impairment (cirrhosis, mild, moderate), renal impairment (mild/moderate, hemodialysis), CYP2D6 metabolizer status, age over 60 years, and gender. The x-axis represents change relative to the reference value, highlighting variability in venlafaxine exposure.*

FDA Label Image

Figure2 (Figure2)

A fold change and 90% confidence interval chart showing the pharmacokinetic effects (Cmax, AUC, ODV Cmax, ODV AUC) of various interacting drugs on venlafaxine and its metabolite ODV. The chart compares changes relative to the control value for interactions with ethanol, diazepam, cimetidine, ketoconazole (in CYP2D6 EMs and PMs), indinavir, metoprolol, imipramine, and lithium.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart showing the fold change and 90% confidence intervals of pharmacokinetic parameters (Cmax and AUC) for various analytes like ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium when interacting with another drug. The x-axis represents change relative to the reference value ranging from 0 to 3, with points and error bars for each analyte and pharmacokinetic metric.*

FDA Label Image

Structure (Structure)

Chemical structure of venlafaxine hydrochloride, showing its molecular components including a cyclohexanol ring, a methoxyphenyl group, and a dimethylaminoethyl side chain, with notation indicating it is the hydrochloride salt and includes an enantiomer.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.